BiotechTube
Home/Pipeline/BGC101

BGC101

Chronic Limb‑Threatening Ischemia (CLTI)

Phase 2Active

Key Facts

Indication
Chronic Limb‑Threatening Ischemia (CLTI)
Phase
Phase 2
Status
Active
Company
BioGenCell

About BioGenCell

Israeli cell‑therapy pioneer developing autologous blood‑derived treatments for microvascular and broader regenerative diseases.

View full company profile

Therapeutic Areas

VascularCardiovascularNeurologyOncologyImmunologyRegenerative Medicine